Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H8I3N2O4.Na |
Molecular Weight | 635.8954 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I
InChI
InChIKey=WCIMWHNSWLLELS-UHFFFAOYSA-M
InChI=1S/C11H9I3N2O4.Na/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20;/h1-2H3,(H,15,18)(H,16,17)(H,19,20);/q;+1/p-1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28028385 | https://www.ncbi.nlm.nih.gov/pubmed/26573558 | https://www.ncbi.nlm.nih.gov/pubmed/18650405
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28028385 | https://www.ncbi.nlm.nih.gov/pubmed/26573558 | https://www.ncbi.nlm.nih.gov/pubmed/18650405
Iothalamic Acid is an iodine-containing organic anion used as a radiocontrast agent. It is available as sodium iothalamate (Iothalamate sodium) and meglumine iothalamate (Iothalmate meglumine). It can be administered intravenously or intravesically (into the urinary bladder). Iothalamate is indicated to visualize specific regions of the vascular system and blood flow in these areas to help in the diagnosis and evaluation of neoplasms (known or suspected) or vascular diseases (congenital or acquired) that may cause changes in normal vascular anatomy or physiology. Iothalamate meglumine injection is indicated for use in cerebral angiography, peripheral arteriography or venography, arterial digital subtraction angiography1 , and intravenous digital subtraction angiography. Iothalamate meglumine and iothalamate sodium injection is indicated for use in selective coronary arteriography, selective renal arteriography, and in intravenous digital subtraction angiography. othalamate meglumine and iothalamate sodium injection and iothalamate sodium injection are indicated to visualize the aorta and its major branches. However, the injection of iothalamate meglumine and iothalamate sodium is preferred because it generally causes less severe hemodynamic, neurotoxic, and cardiotoxic effects than the individual injection of iothalamate sodium. Radioactive formulation is also available as sodium iothalamate I-125 Injection (GLOFIL-125). It is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of patients with renal disease.
CNS Activity
Approval Year
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
64 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3230149 |
63 mmol single, intravascular dose: 63 mmol route of administration: Intravascular experiment type: SINGLE co-administered: |
IOTHALAMIC ACID serum | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
90.45% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11403171 |
IOTHALAMIC ACID plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.5 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.5 |
Disc. AE: Thromboembolic event, Myocardial infarction... AEs leading to discontinuation/dose reduction: Thromboembolic event (serious) Sources: Page: p.5Myocardial infarction (serious) Stroke (serious) Paralysis |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.6 |
Disc. AE: Convulsions, Skin and subcutaneous conditions NEC... AEs leading to discontinuation/dose reduction: Convulsions Sources: Page: p.6Skin and subcutaneous conditions NEC (severe) |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.7 |
Disc. AE: Stevens-Johnson syndrome, Toxic epidermal necrolysis... AEs leading to discontinuation/dose reduction: Stevens-Johnson syndrome (severe) Sources: Page: p.7Toxic epidermal necrolysis (severe) Acute generalized exanthematous pustulosis (severe) Drug reaction with eosinophilia and systemic symptoms (severe) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Paralysis | Disc. AE | 200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.5 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.5 |
Myocardial infarction | serious Disc. AE |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.5 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.5 |
Stroke | serious Disc. AE |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.5 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.5 |
Thromboembolic event | serious Disc. AE |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.5 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.5 |
Convulsions | Disc. AE | 200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.6 |
Skin and subcutaneous conditions NEC | severe Disc. AE |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.6 |
Acute generalized exanthematous pustulosis | severe Disc. AE |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.7 |
Drug reaction with eosinophilia and systemic symptoms | severe Disc. AE |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.7 |
Stevens-Johnson syndrome | severe Disc. AE |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.7 |
Toxic epidermal necrolysis | severe Disc. AE |
200 mL single, intravenous Recommended Dose: 200 mL Route: intravenous Route: single Dose: 200 mL Sources: Page: p.7 |
unhealthy Health Status: unhealthy Condition: Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography Sources: Page: p.7 |
PubMed
Title | Date | PubMed |
---|---|---|
[Recurrent aseptic meningitis (Mollaret meningitis)--spontaneous and drug-induced origin]. | 1991 Dec |
|
Comparison of unenhanced and contrast-enhanced spiral CT for assessing interval change in patients with colorectal liver metastases. | 2001 Aug |
|
Functional effects of renal artery stent placement on treated and contralateral kidneys. | 2002 Aug |
|
Inadvertent intrathecal use of ionic contrast agent. | 2002 Dec |
|
Effects of intrathecal injection of diatrizoate on dopamine receptors. | 2002 Jul |
|
Glomerular filtration rate in children with solid tumors: normative values and a new method for estimation. | 2003 Jun |
|
Salutary effects of radiopaque contrast media on the survival of random-pattern skin flaps in the rat: an experimental study. | 2004 |
|
Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. | 2004 Dec 21 |
|
Summaries for patients. Estimating kidney function in healthy people. | 2004 Dec 21 |
|
Decline in native renal function early after bladder-drained pancreas transplantation alone. | 2004 Mar 27 |
|
Effect of contrast media on vascular smooth muscle cells. | 2004 Oct |
|
[Methods for the quantification of left ventricular volumes assessed by radionuclide ventriculography (first part)]. | 2005 |
|
An alternative formula to the Cockcroft-Gault and the modification of diet in renal diseases formulas in predicting GFR in individuals with type 1 diabetes. | 2005 Apr |
|
Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. | 2005 Aug |
|
Analysis of iodinated X-ray contrast agents in water samples by ion chromatography and inductively-coupled plasma mass spectrometry. | 2005 Aug 26 |
|
Influence of iothalamate on renal medullary perfusion and oxygenation in the rat. | 2005 Dec |
|
Simultaneous determination of anions in nanoliter volumes. | 2005 Jan |
|
[Pancreas anulare as an incidental finding in multidetector computer tomography for symptomatic abdominal aortic aneurysm]. | 2006 Apr |
|
Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients? | 2006 Aug |
|
A novel approach to flexor hallucis longus tenography. | 2006 Dec |
|
Virtual cystoscopy by intravesical instillation of dilute contrast medium: preliminary experience. | 2006 Mar |
|
Prospective comparison of helical CT of the abdomen and pelvis without and with oral contrast in assessing acute abdominal pain in adult Emergency Department patients. | 2006 May |
|
Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. | 2006 Oct 10 |
|
Preemptive living donor kidney transplantation: do the benefits extend to all recipients? | 2007 Jan 27 |
|
[Renal radionuclide scintigraphy in the evaluation of radiopaque substances on renal function]. | 2007 Jan-Feb |
|
Iodide mumps after contrast media imaging: a rare adverse effect to iodine. | 2007 Jul |
|
Elevated vascular endothelial growth factor levels are associated with aortopulmonary collateral vessels in patients before and after the Fontan procedure. | 2007 Jun |
|
Evaluation of the effects of noniodinized and iodinized ionic contrast media and gadoteric acid in acute necrotizing pancreatitis: experimental study in rabbits. | 2007 Nov |
|
Duplicated ectopic ureter with vaginal insertion: 3D CT urography with i.v. and percutaneous contrast administration. | 2007 Nov |
|
Efficacy of single-session percutaneous drainage and 50% acetic Acid sclerotherapy for treatment of simple renal cysts. | 2007 Nov-Dec |
|
Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. | 2007 Sep 27 |
|
Inadvertent intrathecal administration of ionic contrast medium to a dog. | 2007 Sep-Oct |
|
Experimental study of intracranial hematoma detection with flat panel detector C-arm CT. | 2008 Apr |
|
Multidetector computed tomographic angiography in isolated third nerve palsy. | 2008 Aug |
|
Gradient-recalled echo sequences in direct shoulder MR arthrography for evaluating the labrum. | 2008 Jan |
|
Coraco- or costoclavicular paraosteoarthropathies in patients with severe central neurological disorders. | 2008 Mar |
|
Sweet's syndrome-like neutrophilic dermatosis resulting from exposure to a radiocontrast agent. | 2008 Mar |
Patents
Sample Use Guides
For carotid angiography—Percutaneous or via catheter, 5 to 12 mL of a solution containing the equivalent of 282 mg of iodine per mL, repeated as needed.
For vertebral angiography— Percutaneous or via catheter, 4 to 10 mL of a solution containing the equivalent of 282 mg of iodine per mL, repeated as needed.
For retrograde brachial cerebral angiography— Percutaneous, 35 to 50 mL of a solution containing the equivalent of 282 mg of iodine per mL as a single dose, administered rapidly into the brachial artery.
Route of Administration:
Intravascular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1998838
Since the kidneys were perfused at constant flow, changes in renal perfusion pressure were directly proportional to changes in renal vascular resistance (RVR). The basal renal perfusion pressure was constant throughout each experiment varying between 60 and 80mmHg in different preparations. Each kidney was equilibrated for a 30- minute period prior to the addition of sodium iothalamate via a syringe pump linked to the perfusion line. Recovery to baseline was obtained between individual infusions in any one preparation. The contrast media solution in the syringe pump is termed the infusate, while the solution perfusing the kidney is termed the renal perfusate. Concentration response experiments were performed in each preparation. A 70% solution of sodium iothalamate (Conray 420) was infused into the perfusate line for 10-minute periods at predetermined rates to produce a range of iothalamate concentrations in the renal perfusate varying from 0.07% to 4.2%
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28500
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
214-955-8
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | |||
|
m6377
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT001421
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | |||
|
1225-20-3
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | |||
|
C47569
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | |||
|
9886
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID1057668
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | |||
|
100000086431
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | |||
|
SUB02754MIG
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | |||
|
KDN276D83N
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | |||
|
23667529
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201300
Created by
admin on Fri Dec 15 15:05:40 GMT 2023 , Edited by admin on Fri Dec 15 15:05:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD